ALT - Altimmune Inc Stock Price, Fair Value and News

8.00USD-0.90 (-10.11%)Market Closed

Market Summary

USD8.00-0.90

Market Closed

-10.11%

ALT Stock Price

View Fullscreen

ALT RSI Chart

ALT Valuation

Market Cap

567.2M

Price/Earnings (Trailing)

-6.11

Price/Sales (Trailing)

1.3K

EV/EBITDA

-5.03

Price/Free Cashflow

-7.79

ALT Price/Sales (Trailing)

ALT Profitability

EBT Margin

-22930.75%

Return on Equity

-53.64%

Return on Assets

-49.25%

Free Cashflow Yield

-12.84%

ALT Fundamentals

ALT Revenue

Revenue (TTM)

426.0K

Rev. Growth (Yr)

221.74%

Rev. Growth (Qtr)

-89.78%

ALT Earnings

Earnings (TTM)

-92.8M

Earnings Growth (Yr)

-21.52%

Earnings Growth (Qtr)

22.9%

Breaking Down ALT Revenue

Last 7 days

10.8%

Last 30 days

13.6%

Last 90 days

-8.7%

Trailing 12 Months

79.8%

How does ALT drawdown profile look like?

ALT Financial Health

Current Ratio

16.55

Debt/Equity

Debt/Cashflow

-123.28

ALT Investor Care

Shares Dilution (1Y)

43.84%

Diluted EPS (TTM)

-1.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	0	0	0	426.0K
2022	0	0	0	0
2021	6.8M	6.2M	3.4M	4.4M
2020	5.1M	4.2M	6.4M	8.2M
2019	10.6M	9.8M	7.8M	5.8M
2018	13.1M	12.5M	10.6M	10.3M
2017	3.1M	5.4M	9.0M	10.7M
2016	4.6M	4.2M	3.9M	3.8M
2015	13.5M	11.0M	11.2M	10.6M
2014	15.2M	14.5M	12.0M	10.2M
2013	25.5M	23.5M	20.3M	17.9M
2012	24.1M	24.0M	25.4M	25.2M
2011	21.8M	22.6M	23.4M	24.3M
2010	0	0	0	21.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Altimmune Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 02, 2024	roberts m scot	acquired	-	-	7,775	chief scientific officer
Feb 02, 2024	garg vipin k	acquired	-	-	18,950	president and ceo
Feb 02, 2024	garg vipin k	sold (taxes)	-78,064	9.32	-8,376	president and ceo
Feb 02, 2024	roberts m scot	sold (taxes)	-21,715	9.32	-2,330	chief scientific officer
Feb 02, 2024	harris matthew scott	sold (taxes)	-21,734	9.32	-2,332	chief medical officer
Feb 02, 2024	harris matthew scott	acquired	-	-	7,775	chief medical officer
Feb 01, 2024	garg vipin k	acquired	-	-	16,545	president and ceo
Feb 01, 2024	roberts m scot	sold (taxes)	-17,793	9.88	-1,801	chief scientific officer
Feb 01, 2024	roberts m scot	acquired	-	-	6,166	chief scientific officer
Feb 01, 2024	garg vipin k	sold (taxes)	-72,252	9.88	-7,313	president and ceo

Which funds bought or sold ALT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	517	449,118	546,971	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-82.5	-5,495,940	1,034,050	-%
May 16, 2024	Tidal Investments LLC	new	-	140,759	140,759	-%
May 16, 2024	COMERICA BANK	new	-	7,513	7,513	-%
May 16, 2024	Arete Wealth Advisors, LLC	sold off	-100	-137,250	-	-%
May 15, 2024	Walleye Capital LLC	added	47.47	88,817	354,396	-%
May 15, 2024	SILVERARC CAPITAL MANAGEMENT, LLC	sold off	-100	-1,687,500	-	-%
May 15, 2024	Atom Investors LP	sold off	-100	-308,385	-	-%
May 15, 2024	Diametric Capital, LP	sold off	-100	-204,401	-	-%
May 15, 2024	OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)	added	65.59	192,321	578,173	0.04%

Are Funds Buying or Selling ALT?

Are funds buying ALT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ALT

No. of Funds

Unveiling Altimmune Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	state street corp	12.20%	8,649,270	SC 13G/A
Mar 05, 2024	millennium management llc	5.4%	2,911,937	SC 13G
Feb 14, 2024	ameriprise financial inc	7.79%	4,183,682	SC 13G
Feb 14, 2024	nuveen asset management, llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	teachers advisors, llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	tiaa cref investment management llc	0.01%	6,679	SC 13G/A
Feb 14, 2024	avidity partners management lp	0.0%	0	SC 13G/A
Feb 14, 2024	tang capital partners lp	5.1%	2,750,000	SC 13G/A
Feb 13, 2024	vanguard group inc	6.65%	3,571,972	SC 13G/A
Feb 12, 2024	janus henderson group plc	0.0%	273	SC 13G/A

Recent SEC filings of Altimmune Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
Apr 10, 2024	SC 13G/A	Major Ownership Report
Mar 27, 2024	S-8	Employee Benefits Plan
Mar 27, 2024	8-K	Current Report
Mar 27, 2024	10-K	Annual Report
Mar 05, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Altimmune Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Altimmune Inc News

Latest updates

Altimmune Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	37,000	362,000	6,000	21,000	11,500	2,000	8,000	1,642,500	3,277,000	158,000	137,000	838,000	2,312,706	2,937,991	721,636	2,212,694	575,802	643,978	1,626,029	2,955,592
Operating Expenses	-20.4%	26,799,000	33,660,000	22,902,000	18,013,000	21,780,000	22,984,000	24,754,000	20,403,000	19,531,000	27,262,000	33,362,000	25,001,000	15,699,000	13,062,501	21,262,213	19,139,606	9,519,448	4,887,912	11,917,358	5,176,913	5,284,153
S&GA Expenses	-100.0%	-	4,332,000	4,514,000	4,760,000	4,531,000	3,805,000	4,492,000	4,410,000	4,427,000	3,777,000	4,156,000	3,659,000	3,821,000	4,111,929	4,220,238	2,545,356	2,331,917	2,014,823	2,187,661	2,231,817	2,066,482
R&D Expenses	27.1%	21,487,000	16,909,000	18,388,000	13,253,000	17,249,000	19,179,000	20,262,000	15,993,000	15,104,000	20,185,000	29,206,000	13,272,000	11,878,000	8,950,572	17,041,975	16,594,250	7,187,531	2,873,089	8,729,697	2,945,096	3,217,671
EBITDA Margin	0.0%	-228	-228	-20.64	-23.45	-23.31	-23.19	-23.96	-21.86	-21.87	-21.89	-24.15	-10.96	-9.07	-	-	-	-	-	-	-	-
Interest Expenses	-50.0%	1,000	2,000	29,000	2,000	2,000	-183,000	64,000	65,000	62,000	-62,000	33,000	22,000	12,000	1,953	2,275	3,308	1,885	-	756	748	740
Income Taxes	-	-	-	-	-	-	3,000	-197,000	-	-	-	-	-	-	-110,346	-482,017	-1,578,782	-3,245,879	-	-58,500	-	-
Earnings Before Taxes	100.0%	-	-31,641,000	-20,671,000	-	-	-21,660,000	-23,713,000	-	-	-23,889,092	-33,510,000	-24,826,707	-14,864,108	-10,732,123	-18,252,152	-18,345,698	-7,131,528	-4,096,625	-10,997,812	-3,386,888	-2,097,306
EBT Margin	0%	-229	-229	-20.39	-23.30	-23.30	-23.30	-24.02	-22.02	-22.02	-22.02	-24.36	-11.03	-9.13	-	-	-	-	-	-	-	-
Net Income	22.9%	-24,394,000	-31,641,000	-20,671,000	-16,061,000	-20,074,000	-21,660,000	-23,516,000	-20,107,000	-19,430,000	-23,889,000	-33,510,000	-24,827,000	-14,864,000	-10,621,777	-17,770,135	-16,766,916	-3,885,649	-4,096,625	-10,939,312	-3,386,888	-2,097,306
Net Income Margin	-4.9%	-217	-207	-17.79	-18.44	-19.36	-19.21	-19.71	-21.98	-23.05	-22.02	-24.33	-10.94	-8.81	-	-	-	-	-	-	-	-
Free Cashflow	1.1%	-16,357,000	-16,533,000	-20,487,000	-19,379,000	-19,458,000	-17,344,000	-15,110,000	-16,723,000	-13,535,000	-22,114,000	-17,845,000	-26,618,000	-23,778,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-10.6%	188	211	167	183	187	207	225	210	206	219	237	257	264	245	233	103	54.00	54.00	56.00	62.00	65.00
Current Assets	-10.5%	188	210	153	170	173	193	211	196	191	204	218	239	245	230	218	88.00	40.00	39.00	42.00	46.00	49.00
Cash Equivalents	-41.5%	79.00	135	87.00	102	105	111	127	136	180	190	175	174	150	116	144	65.00	11.00	9.00	11.00	42.00	45.00
Net PPE	-16.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	5.00	5.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	-6.8%	15.00	17.00	16.00	16.00	19.00	22.00	20.00	15.00	21.00	20.00	28.00	16.00	18.00	19.00	33.00	23.00	12.00	9.00	7.00	6.00	6.00
Current Liabilities	-6.7%	11.00	12.00	12.00	11.00	15.00	17.00	16.00	14.00	19.00	18.00	19.00	9.00	10.00	12.00	6.00	5.00	6.00	4.00	2.00	3.00	4.00
Shareholder's Equity	-10.9%	173	194	150	168	168	185	205	195	185	199	209	241	246	226	200	80.00	42.00	46.00	49.00	56.00	59.00
Retained Earnings	-5.2%	-490	-466	-434	-414	-397	-377	-356	-332	-312	-293	-269	-235	-210	-186	-175	-158	-141	-137	-133	-122	-118
Additional Paid-In Capital	0.5%	669	665	590	587	571	568	567	532	503	497	484	482	462	417	381	243	188	188	188	184	183
Shares Outstanding	0.3%	71.00	71.00	53.00	53.00	49.00	49.00	49.00	44.00	44.00	41.00	41.00	41.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	184	-	-	-	538	-	-	-	387	-	-	-	281	-	-	-	29.00	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	1.1%	-16,357	-16,533	-20,487	-19,383	-19,407	-17,306	-15,050	-16,704	-13,526	-21,967	-17,775	-18,927	-19,569	-13,282	-9,504	-7,170	-4,347	-2,002	-2,426	-3,060	-2,112
Share Based Compensation	47.8%	3,650	2,469	2,710	2,786	2,675	1,892	2,128	2,048	2,033	1,319	1,497	1,485	1,218	710	1,320	331	215	279	288	290	408
Cashflow From Investing	-396.6%	-39,521	-7,959	4,402	3,987	13,302	981	-25,403	-48,968	-9.00	24,869	18,411	25,078	19,165	-36,999	-47,888	6,098	6,563	-52.68	-28,216	-12.85	-4.25
Cashflow From Financing	-100.4%	-261	72,754	588	13,065	-302	-43.00	32,060	21,583	3,181	12,535	125	18,019	34,419	22,704	136,146	54,539	97.00	45.00	-55.79	-156	12,699

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ALT Income Statement

2024-03-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenues	$ 5	$ 21
Operating expenses:
Research and development	21,487	17,249
General and administrative	5,312	4,531
Total operating expenses	26,799	21,780
Loss from operations	(26,794)	(21,759)
Other income (expense):
Interest expense	(1)	(2)
Interest income	2,413	1,668
Other income (expense), net	(12)	19
Total other income (expense), net	2,400	1,685
Net loss	(24,394)	(20,074)
Other comprehensive income - unrealized (loss) gain on short-term investments	(157)	126
Comprehensive loss	$ (24,551)	$ (19,948)
Net loss per share, basic	$ (0.34)	$ (0.40)
Net loss per share, diluted	$ (0.34)	$ (0.40)
Weighted-average common shares outstanding, basic	70,801,713	50,125,685
Weighted-average common shares outstanding, diluted	70,801,713	50,125,685

ALT Balance Sheet

2024-03-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 78,978	$ 135,117
Restricted cash	41	41
Total cash, cash equivalents and restricted cash	79,019	135,158
Short-term investments	103,046	62,698
Accounts and other receivables	307	1,111
Income tax and R&D incentive receivables	2,272	3,742
Prepaid expenses and other current assets	2,871	6,917
Total current assets	187,515	209,626
Property and equipment, net	544	651
Other assets	299	363
Total assets	188,358	210,640
Current liabilities:
Accounts payable	3,760	2,070
Accrued expenses and other current liabilities	7,573	10,073
Total current liabilities	11,333	12,143
Noncurrent liabilities	4,088	4,398
Total liabilities	15,421	16,541
Commitments and contingencies (Note 10)
Stockholders' equity:
Common stock, $0.0001 par value; 200,000,000 shares authorized; 70,899,134 and 70,677,400 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	668,816	665,427
Accumulated deficit	(490,725)	(466,331)
Accumulated other comprehensive loss, net	(5,161)	(5,004)
Total stockholders' equity	172,937	194,099
Total liabilities and stockholders' equity	$ 188,358	$ 210,640

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

CEO	Dr. Vipin K. Garg Ph.D.
WEBSITE	https://altimmune.com
INDUSTRY	Biotechnology
EMPLOYEES	52

Altimmune Inc Frequently Asked Questions

What is the ticker symbol for Altimmune Inc? What does ALT stand for in stocks?

ALT is the stock ticker symbol of Altimmune Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Altimmune Inc (ALT)?

As of Fri May 17 2024, market cap of Altimmune Inc is 567.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers.

What is the fair value of ALT stock?

You can check ALT's fair value in chart for subscribers. The fair value of Altimmune Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Altimmune Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ALT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Altimmune Inc a good stock to buy?

The fair value guage provides a quick view whether ALT is over valued or under valued. Whether Altimmune Inc is cheap or expensive depends on the assumptions which impact Altimmune Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALT.

What is Altimmune Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, ALT's PE ratio (Price to Earnings) is -6.11 and Price to Sales (PS) ratio is 1.33 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Altimmune Inc's stock?

In the past 10 years, Altimmune Inc has provided -0.172 (multiply by 100 for percentage) rate of return.